World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of personality disorders

World Journal of Biological Psychiatry

Volumn 8, Issue 4, 2007, Pages 212-244

  Herpertz, Sabine ^a   Zanarini, Mary ^b   Schulz, Charles ^c   Siever, Larry ^d   Lieb, Klaus ^e   Möller, Hans Jürgen ^f  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b MCLEAN HOSPITAL   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Antidepressants; Anxious avoidant personality disorder; Biological treatment; Borderline personality disorder; Evidence based guidelines; Mood stabilizer; Neuroleptics; Pharmacotherapy; Schizotypal personality disorder

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BROFAROMINE; CARBAMAZEPINE; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; MIANSERIN; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; PHENELZINE; PLACEBO; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; TOPIRAMATE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE; UNINDEXED DRUG; VALPROATE SEMISODIUM;

ADOLESCENT DISEASE; AGITATION; ANOREXIA; AVOIDANT PERSONALITY DISORDER; BIOLOGICAL THERAPY; BORDERLINE STATE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHILD CARE; CLINICAL PROTOCOL; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIABETES INSIPIDUS; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HUMAN; LIBIDO DISORDER; LOW DRUG DOSE; MEDICAL SOCIETY; MONOTHERAPY; MOTOR DYSFUNCTION; NAUSEA; PARESTHESIA; PERSONALITY DISORDER; PREVALENCE; PROGNOSIS; PSYCHOTHERAPY; REVIEW; RISK FACTOR; SCHIZOTYPAL PERSONALITY DISORDER; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VISUAL IMPAIRMENT; WEIGHT REDUCTION; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BORDERLINE PERSONALITY DISORDER; EVIDENCE-BASED MEDICINE; HUMANS; PERSONALITY DISORDERS; PSYCHIATRY; PSYCHOTHERAPY; SCHIZOTYPAL PERSONALITY DISORDER; SOCIETIES, MEDICAL;

EID: 35548939470     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.1080/15622970701685224     Document Type: Review

References (171)

1. Alden, LE, Paosa, JM, Taylor, CT and Ryder, AG (2002) Avoidant personality disorder: Current status and future directions. J Pers Disord, 16, pp. 1-29.
2. Allgulander, C. (1999) Paroxetine in social anxiety disorder: A randomized placebo-controlled study. Acta Psychiatr Scand, 100, pp. 193-198.
3. Allgulander, C., Mangano, R. and Zhang, J. (2004) Efficacy of venlafaxine ER in patients with social anxiety disorder: A double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol, 19, pp. 387-396.
4. American Psychiatric Association (2001) Practice giudeline for the treatment of patients with boderline personality disorder. Am J Psychiatry, 158, pp. 1-52.
5. Bakker, A., van Balkm, AJ and van Dyck, R. (2000) Selective serotonin reuptake inhibitors in the treatment of panic dosorder and agoraphobia. Int Clin Psychopharmacol, 15, pp. 525-535.
6. Baldwin, D., Bobes, J., Stein, DJ, Scharwachter, I. and Faure, M. (1999) Paroxetine in social phobia/social anxiety disorder. Randomis double-blind, placebo-controlled study. Paroxetine Study. Br J Psychiatry, 175, pp. 120-126.
7. Bateman, A. and Fonagy, P. (1999) Effectiveness of partial hospitalization in the treatment of borderline personality disorder: A randomized controlled trial. Am J Psychiatry, 156, pp. 1563-1569.
8. Bateman, A. and Fonaghy, P. (2001) Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: An 18-month follow-up. Am J Psychiatry, 158, pp. 36-42.
9. Bauer, M., Whybrow, PC, Angst, J., Versiani, M., M-ller, HJ and WFSBP Task Force an Treatment Guidelines for Unipolar Depressive Disorders. (2002) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry, 3, pp. 5-43.
10. Bellino, S., Paradiso, E. and Bogetto, F. (2005) Oxcarbazepine in the treatment of borderline personality disorder: A pilot study. J Clin Psychiatry, 66, pp. 1111-1115.
11. Bellino, S., Paradiso, E. and Bogetto, F. (2006) Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study. J Clin Psychiatry, 67, pp. 1042-1046.
12. Bellino, S., Zizza, M., Rinaldi, C. and Bogetto, F. (2006) Combined treatment of major depression in patients with borderline personality disorder: A comparison with pharmacotherapy. Can J Psychiatry, 51, pp. 453-460.
13. Bender, DS, Skodol, AE and Pagano, ME (2006) Prospective assessment of treatment use by patients with personality disorders. Psychiatr Serv, 57, pp. 254-247.
14. Benedetti, F., Sforzini, L., Colombo, C., Maffei, C. and Smeraldi, E. (1998) Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry, 59, pp. 103-107.
15. Bergida, H. and Lenzenweger, MF (2006) Schizotypy and sustained attention: Confirming evidence from an adult community sample. J Abnorm Psychol, 115, pp. 545-551.
16. Birmaher, B., Axelson, DA and Monk, K. (2003) Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry, 42, pp. 415-423.
17. Blomhoff, S., Haug, TT and Hellstrom, K. (2001) Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry, 179, pp. 23-30.
18. Bogenschutz, MP and Nurnberg, H George (2004) Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry, 65, pp. 104-109.
19. Bohus, M., Stieglitz, RD, Fiedler, P. and Berger, M. (1999) Psychiatrie und Psychotherapie, pp. 771-846.
20. Brown, GK, Newman, CF, Charlesworth, SE, Crits-Christiph, P. and Beck, AT (2004) An open clinical trial of cognitive therapy for borderline personality disorder. J Personal Dosord, 18, pp. 257-271.
21. Chengappa, KN, Ebeling, T., Kang, JS, Levine, J. and Parepally, H. (1999) Clozapine reduces severe self-multilation and aggression in psychotic patients with borderline personality disorder. J Clin Psychiatry, 60, pp. 477-484.
22. Clark, DM, Ehlers, A. and Hackmann, A. (2006) Cognotive therapy and exposure plus applied relaxation in the treatment of social phobia. J Consult Clin Psychol, 74, pp. 568-578.
23. Clarkin, JF, Levy, KN, Lenzenweger, MF and Kernberg, OF (2004) The Personality Disorders Institute/Borderline Personality Disorder Research Foundation randomized control trial for borderline personality disorder: Rationale, methods, and patient characteristics. J Personal Disord, 18, pp. 52-72.
24. Clarkin, JF, Levy, KN, Lenzenweger, MF and Kernberg, OF (2007) Evaluating three treatments for borderline personality disorder: A multiwave study. Am J Psychiatry, 164, pp. 922-928.
25. Coccaro, EF and Kavoussi, RJ (1997) Fluoxetine and impulsive aggressive behaviour in personality-disordered subjects. Arch Gen Psychiatry, 54, pp. 1081-1088.
26. Cochrane Database of Systematic Reviews (2006) Pharmacological Interventions for People with Borderline Personality Disorder.
27. Coid, JW (1992) DSM-III diagnosis in criminal psychopaths: A way forward. Crim Behav Ment Health, 2, pp. 78-94.
28. Cornelius, JR, Soloff, PH, Perel, JM and Ulrich, RF (1993) Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. Am J Psychiatry, 150, pp. 1843-1848.
29. Cowdry, RW and Gardner, DL (1988) Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry, 45, pp. 111-119.
30. Davidson, J., Yaryura-Tobias, J. and DuPont, R. (2004) Fluoxamine-controlled release formulation for the treatment of generalizes social anxiety disorder. J Clin Psychopharmacol, 24, pp. 118-125.
31. Davidson, JR, Foa, EB and Huppert, JD (2004) Fluoxetine, comprehensive cognitive behavioural therapy, and placebo in generalized social phobia. Arch Gen Psychiatry, 61, pp. 1005-1013.
32. Davidson, K., Norrie, J. and Tyrer, P. (2006) The effectiveness of cognitive behaviour therapy for borderline personality disorder: Results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. J Pers Disord, 20, pp. 450-465.
33. de la Fuente, JM and Lotstra, F. (1994) A Trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol, 4, pp. 470-486.
34. Dolan-Sewell, RT, Krueger, RF and Shea, MT (2001) Co-occurrence with syndrome disorders. Handbook of personality dosorders: Theory, research, and treatment, The Guilford Press, New York, London
35. Fahlen, T., Nilsson, HL, Borg, K., Humble, M. and Pauli, U. (1995) Social phobia: The clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study. Acta Psychiatr Scand, 92, pp. 351-358.
36. Fawcett, J. and Barkin, RL (1998) A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. J Clin Psychiatry, 59, pp. 123-127.
37. Frankenburg, FR and Zanarini, MC (1993) Clozapine treatment of borderline patients: A preliminary study. Compr Psychiatry, 34, pp. 402-405.
38. Frankenburg, FR and Zanarini, MC (2002) Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: A double-blind placebo-controlled pilot study. J Clin Psychiatry, 63, pp. 442-446.
39. Frankenburg, FR and Zanarini, MC (2004) The association between borderline personality disorder and chronic medical illnesses, poor health-related lifestyle choices, and costly forms of health care utilization. J Clin Psychiatry, 65, pp. 1660-1665.
40. Frankenburg, FR and Zanarini, MC (2006) Obesity and obesity-related illnesses in borderline patients. J Pers Disord, 20, pp. 71-80.
41. Giesen-Bloo, J., van Dyck, R. and Spinhoven, P. (2006) Qutpatient psychotherapy for borderline personality disorder: Randomized trial of schema-focused therapy vs transference-focused psychotherapy. Arch Gen Psychiatry, 63, pp. 649-658.
42. Goldberg, SC, Schulz, SC, Schulz, PM, Resnick, RJ, Hamer, RM and Friedel, RO (1986) Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry, 43, pp. 680-686.
43. Grilo, CM, Sanislow, CA and Gunderson, JG (2004) Two-Year stability and change of schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders. J Consult Clin Psychol, 72, pp. 767-775.
44. Gruettert, T. and Friege, L. (2005) Quetiapine in patients with borderline personality disorder and psychosis: A case series. Int J Psychiatry Clin Pract, 9, pp. 180-186.
45. Gunderson, JG, Weinberg, I. and Daversa, MT (2006) Descriptive and longitudinal observations on the relationship of borderline personality disorder and bipolar disorder. Am J Psychiatry, 163, pp. 1173-1178.
46. Hazell, P., O'Conell, D., Heathcote, D. and Henry, D. Tricyclics in child and adolescent depression (Cochrane Review).
47. Hamazaki, T., Sawazaki, S. and Itomura, M. (1996) The effect of docosahexaenoic acid on aggression in young adults. A placebo-controlled double-blind study. J Clin Invest, 97, pp. 1129-1133.
48. Hamazaki, T., Thienprasert, A., Kheovichai, K., Samuhaseneetoo, S., Nagasawa, T. and Watanabe, S. (2002) The effect of docosahexaenoic acid on aggression in elderly Thai subjects - A placebo-controlled double-blind study. Nutr Neurosci, 5, pp. 37-41.
49. Harb, GC, Heimberg, RG, Fresco, DM, Schneier, FR and Liebowitz, MR (2002) The psychometric properties of the interpersonal sensitivity measure in social anxiety disorder. Behav Res Ther, 40, pp. 961-979.
50. Hedges, DW, Brown, BL, Shwalb, DA, Godfrey, K. and Larcher, AM (2006) The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: A meta-analysis of double-blind, placebo-controlled trials. J Psychopharmacol, 21, pp. 102-111.
51. Heimberg, RG, Liebowitz, MR and Hope, DA (1998) Cognitive behavioural group therapy ys phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry, 55, pp. 1133-1141.
52. Heinze, M., Andreae, D. and Grohmann, R. (2005) Pharmacotherapy of personatity disorders in german speaking countries: State and changes in the last decade. Pharmacopsychiatry, 38, pp. 201-205.
53. Herbert, JD and Bellack, DA (1992) Validity of the distinction between generalized social phobia and avoidant personality disorder. J Abnorm Psychol, 101, pp. 332-339.
54. Hollander, E., Allen, A. and Lopez, RP (2001) A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry, 62, pp. 199-203.
55. Hollander, E., Tracy, KA and Swann, AC (2003) Divalproex in the treatment of impulsive aggression: Efficacy in cluster b personality disorders. Neuropsychopharmacology, 28, pp. 1186-1197.
56. Hollander, E., Swann, AC, Coccaro, EF, Jiang, P. and Smith, TB (2005) Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry, 162, pp. 621-624.
57. Johnson, JG, Cohen, P., Kasen, S., Skodol, AE, Hamagami, F. and Brook, JS (2000) Age-related change in personality disorder trait levels between early adolescence and adulthood: Acommunity-based longitudinal investigastion. Acta Psychiatr Scand, 102, pp. 265-275.
58. Kasper, S., Stein, DJ, Loft, H. and Nil, R. (2005) Escitalogram in the treatment of social anxiety disorder: Randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry, 186, pp. 222-226.
59. Katschnig, H., Amering, M. and Stolk, JM (1995) Long-term follow-up after a drug trial for panic disorder. Br J Psychiatry, 167, pp. 487-494.
60. Katzelnick, DJ, Kobak, KA, Greist, JH, Jefferson, JW, Mantle, JM and Ser, RC (1995) Sertraline for social phobia: A double-blind, placebo-controll crossover study. Am J Psychiatry, 152, pp. 1368-1371.
61. Keshavan, M., Shad, M., Soloff, P. and Schooler, N. (2004) Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder. Schizophr Res, 71, pp. 97-101.
62. Kobak, KA, Greist, JH, Jefferson, JW and Katzelnick, DJ (2002) Fluoxetine in social phobia: A double-blind, placebo-controlled pilot study. J Clin Psychopharmacol, 22, pp. 257-262.
63. Koenigsberg, HW (1991) Borderline personality disorder. Integrating pharmacotherapy and psychotherapy, American Psychiatric Press, Washington, DC
64. Koenigsberg, HW, Reynolds, D. and Goodman, M. (2003) Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry, 64, pp. 628-634.
65. Koons, CR, Robins, CJ and Tweed, JL (2001) Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. Behav Ther, 32, pp. 371-390.
66. Lader, M., Stender, K., Burger, V. and Nil, R. (2004) Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: Randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety, 19, pp. 241-248.
67. Lenzenweger, MF (1999) Stability and change in personality disorder features: The longitudinal study of personatity disorders. Arch Gen Psychiatry, 56, pp. 1009-1015.
68. Lepola, U., Bergtholdt, B., Lambert, J. St., Davy, KL and Ruggiero, L. (2004) Controlled-release paroxetine in the treatment of patients with social anxiety disorder. J Clin Psychiatry, 65, pp. 222-229.
69. Lieb, K., Zanarini, MC, Schmahl, C., Linehan, MM and Bohus, M. (2004) Borderline personality disorder. Lancet, 364, pp. 453-461.
70. Liebowitz, MR, Schneier, F. and Campeas, R. (1990) Phenelzine and atenolol in social phobia. Psychopharm Bull, 26, pp. 123-125.
71. Liebowitz, MR, Schneier, F. and Campeas, R. (1992) Phenelzine vs atenolol in social phobia. Arch Gen Psychiatry, 49, pp. 290-300.
72. Liebowitz, MR, Heimberg, RG and Schneier, FR (1999) Cognitive-behavioral group therapy versus phenelzine in soci phobia: Long-term outcome. Depress Anxiety, 10, pp. 89-98.
73. Liebowitz, MR, Stein, MB, Tancer, M., Carpenter, D., Oakes, R. and Otts, CD (2002) A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry, 63, pp. 66-74.
74. Liebowitz, MR, Gelenberg, AJ and Munjack, D. (2005) Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry, 62, pp. 190-198.
75. Linehan, MM, Amstrong, HE, Suarez, A., Allmon, D. and Heard, HL (1991) Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Arch Gen Psychiatry, 48, pp. 1060-1064.
76. Linehan, MM, Tutek, DA, Heard, HL and Armstrong, HE (1994) Interpersonal outcome of cognitive bheavioral treatment for chronically suicidal borderline patients. Am J Psychiatry, 151, pp. 1771-1776.
77. Linehan, MM, Schmidt 3rd, H., Dimeff, LA, Craft, JC, Kanter, J. and Comtois, KA (1999) Dialectical behavior therapy for patients with borderline personality disorder and drug-dependence. Am J Addict, 8, pp. 279-292.
78. Linehan, MM, Dimeff, LA and Reynolds, SK (2002) Dialectical behavior therapy versus comprehensive validation therapy plus 12-step for the treatment of opioid dependent women meeting criteria for borderline personality disorder. Drug Alcohol Depend, 67, pp. 13-26.
79. Linehan, MM, Comtois, KA and Murray, AM (2006) Two-year randomized controlled trial and follow-up of dialectical behavior theapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Arch Gen Psychiatry, 63, pp. 757-766.
80. Links, PS, Steiner, M., Boiago, I. and Irwin, D. (1990) Lithium therapy for borderline patients: Preliminary findings. J Personal Disord, 4, pp. 173-181.
81. Loew, TH, Nickel, MK and Muehlbacher, M. (2006) Topiramate treatment for women with borderline personality disorder: A double-blind, placebo-controlled study. J Clin Psychopharmacol, 26, pp. 61-66.
82. Loranger, AW, Sartorius, N. and Andreoli, A. (1994) The International Personality Disorders Examination. Arch Gen Psychiatry, 51, pp. 215-224.
83. Lott, M., Greist, JH, Jefferson, JW, Kobak, KA, Katzelnick, DJ and Schaettle, SC (1997) Brofaromine for social phobia: A multicenter, placebo-controlled, double-blind study. J Clin Psychophamacol, 17, pp. 255-260.
84. Lucas, PB, Garnder, DL, Wolkowitz, OM and Cowdry, RW (1987) Dysphoria associated with methylphenidate infusion in borderline personality disorder. Am J Psychiatry, 144, pp. 1577-1579.
85. Markovitz, PJ and Wagner, SC (1995) Venlafaxine in the treatment of borderline personality disorder. Psychopharmacol Bull, 31, pp. 773-777.
86. Markovitz, PJ, Calabrese, JR, Schulz, SC and Meltzer, HY (1991) Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry, 148, pp. 1064-1067.
87. McClure, MM, Romero, MJ, Bowie, CR, Reichenberg, A., Harvey, PD and Siever, LJ (2007) Visual-spatial learning and memory in schizotypal personality disorder: Continued evidence for the importance of working memory in the schizophrenia spectrum. Arch Clin Neuropsychol, 22, pp. 109-116.
88. McGlashan, TH, Grilo, CM and Sanislow, CA (2005) Two-year prevalence and stability of individual DSM-IV criteria for schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders: Toward a hybrid model of axis II disorders. Am J Psychiatry, 162, pp. 883-889.
89. Möller, HJ (1992) Antidepressants - do they decrease or increase suicidality?. Pharmacopsychiatry, 25, pp. 249-253.
90. Montgomery, SA and Montgomery, D. (1982) Pharmacological prevention of suicidal behaviour. J Affect Disord, 4, pp. 291-298.
91. Montgomery, SA and Montgomery, D. (1983) The prevention of recurrent suicidal acts. Br J Clin Pharmacol, 15, pp. 183-188.
92. Montgomery, SA, Nil, R., Durr-Pal, N., Loft, H. and Boulenger, JP (2005) A 24-week randomized, double-blind, placebo-controlled study of excitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry, 66, pp. 1270-1278.
93. New, AS, Buchsbaum, MS and Hazlett, EA (2004) Fluoxetine increases relative metabolic rate in prefrontal cortex in impulsive aggression Psychopharmacology, 176, pp. 451-458.
94. Nickel, MK, Loew, TH and Gil, FP (2007) Aripiprazole in treatment of borderline patients, part II: An 18-month follow-up. Psychopharmacology, 191, pp. 1023-1026.
95. Nickel, MK, Nickel, C. and Mitterlehner, FO (2004) Topiramate treatment of aggression in female borderline personality disorder patients: A douple-blind, placebo-controlled study. J Clin Psychiatry, 65, pp. 1515-1519.
96. Nickel, MK, Nickel, C. and Kaplan, P. (2005) Treatment of aggression with topiramate in male borderline patients: A double-blind, placebo-controlled study. Biol Psychiatry, 57, pp. 495-499.
97. Nickel, MK, Muehlbacher, M. and Nickel, C. (2006) Aripiprazole in the treatment of patients with borderline personality disorder: A double-blind placebo-controlled study. Am J Psychiatry, 163, pp. 833-838.
98. Nordahl, HM and Nysaeter, TE (2005) Schema therapy patients with borderline personality disorder: A single case series. J Behav Ther Exp Psychiatry, 26, pp. 254-264.
99. Norden, MJ (1989) Fluoxetine in borderline personality disorder. Prog Neuropsychopharmacol Biol Psychiatry, 13, pp. 885-893.
100. Nosè, M., Cpriani, A., Biancosino, B., Grassi, L. and Barbui, C. (2006) Efficacy of pharamcotherapy against core traits of borderline personality disorder: Meta-analysis of randomized controlled trials. Int Clin Psychopharmacol, 21, pp. 345-353.
101. Noyes Jr, R., Moroz, G. and Davidson, JR (1997) Moclobemide in social phobia: A controlled dose-response trial. J Clin Psychopharmacol, 17, pp. 247-254.
102. Oldham, JM, Skodol, AE, Kellmann, D., Hyler, SE, Rosnick, L. and Davies, M. (1992) Diagnosis of DSM-III-R personality disorders by two structured interviews: Patterns of comorbidity. Am J Psychiatry, 149, pp. 213-220.
103. Oldham, JM, Bender, DS and Skodol, AE (2004) Testing an APA practice guideline: Symptom-targeted medication utilization for patients with borderline personality disorder. J Psychiatr Pract, 10, pp. 156-161.
104. Pande, AC, Davidson, JRT and Jefferson, JW (1999) Treatment of social phobia with gabapentin: A placebo-controlled study. J Clin Psychopharmacology, 19, pp. 341-348.
105. Pande, AC, Feltner, DE and Jefferson, JW (2004) Efficacy of the novel anxiolytic pregabalin in social anxiety disorder. J Clin Psychopharmakology, 24, pp. 141-149.
106. Parc, S. and McTigue, K. (1997) Working memory and the syndromes of schizotypal personality. Schizophr Res, 29, pp. 213-220.
107. Paris, J. (2005) Outcome and epidemiological research on personality disorders: Implications for classification. J Personal Disord, 19, pp. 557-562.
108. Parker, G. (1998) Personality disorders as alien territory: classification, measurement and border issues. Curr Opin Psychiatry, 11, pp. 125-129.
109. Parker, G., Hadzi-Pavlovic, D. and Roussos, J. (1998) Non-melancholic depression: The contribution of personality, anxiety and life events to subclassification. Psychol Med, 28, pp. 1209-1219.
110. Parsons, B., Quitkin, FM and McGrath, PJ (1989) Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacol Bull, 25, pp. 524-534.
111. Pascual, JC, Oller, S., Soler, J., Barrachina, J., Alvarez, E. and Pérez, V. (2004) Ziprasidone in the acute treatment of borderline personality disorder in psychiatric emergency services. J Clin Psychiatry, 65, pp. 1281-1282.
112. Peet, M. and Stokes, C. (2005) Omega-3 fatty in the treatment of psychiatric disorders. Drugs, 65, pp. 1051-1059.
113. Perrella, C., Carrus, D., Costa, E. and Schifano, F. (2007) Quetiapine for the treatment of borderline personality disorder; an open-label study. Prog Neuropsychopharmacol Biol Psychiatry, 31, pp. 158-163.
114. Perry, JC, Banon, E. and Ianni, F. (1999) Effects of psychotherapy for personality disorders. Am J Psychiatry, 156, pp. 1312-1321.
115. Philipsen, A., Richter, H. and Schmahl, C. (2004) Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. J Clin Psychiatry, 65, pp. 1414-1419.
116. Ralevski, E., Sanislow, CA and Grilo, CM (2005) Avoidant personality disorder and social phobia: Distinct enough to be separate disorders?. Acta Psychiatr Scand, 112, pp. 208-214.
117. Reich, J. (2002) Drug treatment of personality disorder traits. Psychiatr Ann, 32, pp. 590-596.
118. Renneberg, B. Disorder oriented psychotherapy, Elsevier, Muenchen, New York
119. Resarch Units of Pediatric Psychopharmacology Anxiety Study Group (2000) A multi-site double-blind placebo-controlled trail of fluvoxamine for children and adolescents with anxiety disorders. Presented at the 40th New Clinical Drug Evaluation Unit Annual Meeting
120. Rickels, K., Mangano, R. and Khan, A. (2004) A double-blind, placebo-controlled of a flexible dose of venlafaxine er in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacology, 24, pp. 488-496.
121. Rinne, T., Brink, W van den, Wouters, L. and van Dyck, R. (2002) SSRI treatment of borderline personality disorder: A randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry, 159, pp. 2048-2054.
122. Rocca, P., Marchiaro, L., Cocuzza, E. and Bogetto, F. (2002) Treatment of borderline personality disorder with risperidone. J Clin Psychiatry, 63, pp. 241-244.
123. Rodebaugh, TL, Holaway, RM and Heimberg, RG (2004) The treatment of social anxiety disorder. Clin Psych Rev, 24, pp. 883-908.
124. Rudolph, RL, Entsuah, R. and Chitra, R. (1998) A metaanalysis of the effects of venlafaxine on anxiety assciated with depression. J Clin Psychopharmacol, 18, pp. 136-144.
125. Salzmann, C., Wolfson, AN and Schatzberg, A. (1995) Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol, 15, pp. 23-29.
126. Schneier, FR, Gortz, D., Campeas, R., Fallon, B., Marshall, R. and Liebowitz (1998) Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry, 172, pp. 70-77.
127. Schulz, SC, Camlin, KL, Berry, SA and Jesberger, JA (1999) Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry, 46, pp. 1429-1435.
128. Serban, G. and Siegel, S. (1984) Response of bordeline and schizotypal patients to small doses of thiothixene and haloperidol. Am J Psychiatry, 141, pp. 1455-1458.
129. Shea, MT, Stout, R. and Gunderson, J. (2002) Short-term diagnostic stability of schizotypal, borderline, avoidant, and obsessive-compulsive. Am J Psychiatry, 159, pp. 2036-2041.
130. Siever, LJ and Davis, KL (2004) The pathophysiology of schizophrenia disorders: Perspectives from the spectrum. Am J Psychiatry, 161, pp. 398-413.
131. Simeon, D., Baker, B., Chaplin, W., Braun, A. and Hollander, E. (2007) An open-label trial of divalproex extended-release in the treatment of borderline personality disorder. CNS Spectr, 12, pp. 439-443.
132. Simpson, EB, Yen, S. and Cosatello, E. (2004) Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry, 65, pp. 379-385.
133. Skodol, AE, Gunderson, JG and Shea, MT (2005) The collaborative longitudinal personality disorders study (CLPS): Overview and implications. J Pers Disord, 19, pp. 487-504.
134. Soler, J., Pascual, JC and Campins, J. (2005) Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personalaty disorder. Am J Psychiatry, 162, pp. 1221-1224.
135. Soloff, PH, George, A. and Nathan, S. (1989) Amitriptyline versus haloperidol in borderlines: Final outcomes and predictors of response. J Clin Psychopharmacol, 9, pp. 238-246.
136. Soloff, PH, Cornelius, J., George, A., Nathan, S., Perel, JM and Ulrich, RF (1993) Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry, 50, pp. 377-385.
137. Stein, DJ, Mullen, L., Islam, MN, Cohen, L., DeCaria, CM and Hollander, E. (1995) Compulsive and impulsive symptomatology in trichotillomania. Psychopathology, 28, pp. 208-213.
138. Stein, DJ, Versiani, M., Hair, T. and Kumar, R. (2002) Efficacy of paroxetine for relapse prevention in social anxiety disorder. Arch Gen Psychiatry, 59, pp. 1111-1118.
139. Stein, MB, Liebowitz, MR, Lydiard, RB, Pitts, CD, Bushnell, W. and Gergel, I. (1998) Paroxetine treatment of gereralized social phobia (social anxiety disorder): A randomized controlled trial. J Am Med Assoc, 280, pp. 708-713.
140. Stein, MB, Fyer, AJ, Davidson, JR, Pollack, MH and Wiita, B. (1999) Fluoxamine treatment of social phobia (social anxiety disorder): A double-blind, placebo-controlled study. Am J Psychiatry, 156, pp. 756-760.
141. Stein, MB, Sareen, J., Hami, S. and Chao, J. (2001) Pindolol potentiation of paroxetine for generalized social phobia: A double-blind, placebo-controlled, crossover study. Am J Psychiatry, 158, pp. 1725-1727.
142. Stein, MB, Pollack, MH, Bystritsky, A., Kelsey, JE and Mangano, RM (2005) Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: A 6-month randomized controlled trial. Psychopharmalogy, 177, pp. 280-288.
143. Stone, M. (1987) A psychodynamic approach: Some thoughts on the dynamics and therapy of self-mutilating borderline patients. J Pers Disord, 1, pp. 347-349.
144. The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia (1997) Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neurosci, 247, pp. 71-80.
145. Tritt, K., Nickel, C. and Lahmann, C. (2005) Lamotrigine treatment of aggression in female borderline-patients: A randomized, double-blind, placebo-controlled study. J Psychopharmacol, 19, pp. 287-291.
146. Turner, TRM (2000) Naturalistic evaluation of dialectical behavior therapy-oriented treatment for borderl-ne personality disorder. Cognit Behav Practice, 7, pp. 413-419.
147. Van Ameringen, MA, Lane, RM and Walöker, JR (2001) Sertraline treatment of generalized social phobia: A 20-week, double-blind, placebo-controlled study. Am J Psychiatry, 158, p. 275.
148. Van Ameringen, M., Allgulander, C. and Bandelow, B. (2003) WCA recommendations for the long term treatment of social phobia. CNS Spectr, 8, pp. 40-52.
149. Van Ameringen, M., Oakman, J., Mancini, C., Pipe, B. and Chung, H. (2004) Predictors of response in generalized social phobia: Effect of age of onset. J Clin Psychopharmacol, 24, pp. 42-48.
150. Bosch, LM van den, Koeter, MW, Stijnen, T., Verheul, R. and Brink, W van den (2005) Substained efficacy of dialectical behaviour therapy for borderline personality disorder. Behav Res Ther, 43, pp. 1231-1241.
151. van der Linden, GJ, Stein, DJ and van Balkom, AJ (2000) The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): A meta-analysis of randomized controlled trials. Int Clin Psychopharmacol, 2, pp. 15-23.
152. van Vliet, IM, Boer, JA den and Westenberg, HG (1994) Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology (Berlin), 115, pp. 128-134.
153. van Vliet, IM, Boer, JA den, Westenberg, HG and Pian, KL (1997) Clinical effects of buspirone in social phobia: A double-blind placebo-controlled study. J Clin Psychiatry, 58, pp. 164-168.
154. Verheul, R., Bosch, LM Van Den, Koeter, MW, De Ridder, MA, Stijnen, T. and Brink, W Van Den (2003) Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in the netherlands. Br J Psychiatry, 182, pp. 135-140.
155. Versiani, M., Nardi, AE, Mundim, FD, Alves, AB, Liebowitz, MR and Amre, R. (1992) Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br J Psychiatry, 161, pp. 353-360.
156. Villeneuve, E. and Lemelin, S. (2005) Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. J Clin Psychiatry, 66, pp. 1298-1303.
157. Weinberg, I., Gunderson, JG, Hennen, J. and Cutter, CJ (2006) Manual assisted cognitive treatment for deliberate selfharm in borderline personality disorder patients. J Pers Disord, 20, pp. 482-492.
158. Wlch, SS and Linehan, MM (2002) High-risk situations associated with parasuicide and drug use in borderline personality disorder. J Pers Disord, 16, pp. 561-569.
159. Widiger, TA (1992) Generalized social phobia versus avoidant personality disorder: A commentary on three studies. J Abnorm Psychol, 101, pp. 340-343.
160. Widiger, TA and Shea, T. (1991) Differentiation of axis I and axis II disorders. J Abnorm Psychol, 100, pp. 399-406.
161. Wilcox, JA (1995) Divalproex sodium as a treatment for borderline personality disorder. Ann Clin Psychiatry, 7, pp. 33-37.
162. Wong, IC, Besag, FM, Santosh, PJ and Murray, ML (2004) Use of selective serotonin reuptake inhibitors in children and adolescents. Drug Safety, 27, pp. 991-1000.
163. Zanarini, MC and Frankenburg, FR (2001) Olanzapine treatment of female borderline personality disorder patients: A double-blind, placebo-controlled pilot study. J Clin Psychiatry, 62, pp. 849-854.
164. Zanarini, MC, Gunderson, JG, Frankenburg, FR and Chauncey, DL (1990) Discriminating borderline personality disorder from other axis II disorders. Am J Psychiatry, 147, pp. 161-167.
165. Zanarini, MC, Gunderson, JG and Frankenburg, FR (1990) Cognitive features of borderline personality disorder. Am J Psychiatry, 147, pp. 57-63.
166. Zanarini, MC, Frankenburg, FR, Hennen, J. and Silk, KR (2003) The longitudinal course of borderline psychopathology: 6-year prospective follow-up of the phenomenology of borderline personality disorder. Am J Psychiatry, 160, pp. 274-283.
167. Zanarini, MC, Frankenburg, FR, Hennen, J., Reich, DB and Silk, KR (2004) Axis I comorbidity of borderline personality disorder: Description of six-year course and predicition to time-to-remission. Am J Psychiatry, 161, pp. 2108-2114.
168. Zanarini, MC, Frankenburg, FR, Vujanovic, AA, Hennen, J., Reich, DB and Silk, KR (2004) Axis II comorbidity of borderline personality disorder: Description of six-year course and predicition to time-to-remission. Acta Psychiatr Scand, 110, pp. 416-420.
169. Zanarini, MC, Frankenburg, FR and Parachini, EA (2004) A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzaoine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry, 65, pp. 903-907.
170. Zanarini, MC, Frankenburg, FR, Hennen, J., Reich, DB and Silk, KR (2006) Prediction of the 10-year course of borderline personality disorder. Am J Psychiatry, 163, pp. 827-832.
171. Zimmermann, M. and Coryell, W. (1989) DSM-III personality disorder diagnoses in a nonpatient sample. Arch Gen Psychiatry, 46, pp. 682-689.